The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation in Normotensive and Hypertensive Patients
NCT ID: NCT01880931
Last Updated: 2015-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2013-06-30
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation
NCT02001285
The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)
NCT01899248
A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients
NCT01152515
The EC50 of Remifentanil Blunting Hemodynamic Response to Double Lumen Tube Intubation
NCT01542099
Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)
NCT01351285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normotensive patients
To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
Remifentanil
The effect site concentration of remifentanil
Hypertensive patients
To find out the effect site concentration of remifentanil for preventing QTc prolongation \< 15 sec during intubation : Dixon's up-and-down method
Remifentanil
The effect site concentration of remifentanil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remifentanil
The effect site concentration of remifentanil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Severance Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
So Yeon Kim
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
So Yeon Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2013-0239
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.